BACKGROUND: Normalizing growth in children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD-CAH) requires a long-term maintenance of a fragile balance between hydrocortisone (HC) replacement and androgen suppression. The growth pattern in children with 21OHD-CAH diagnosed by clinical symptoms has been evaluated in numerous retrospective studies. The aim of this study was to evaluate growth of patients with 21OHD-CAH detected by newborn screening (NBS), prior to clinical symptoms. METHODS: Nation-wide NBS for 21OHD-CAH was implemented in the Czech Republic in 2006. Since then, 1,317,987 neonates were screened (2006-2017) and 21OHD-CAH was confirmed in 108 patients. Growth was evaluated as height-standard deviation score (SDS) at regular time-points, related to bone age and compared to recent population standards. In 88 patients, available data allowed long-term evaluation of growth, HC and fludrocortisone doses (in half-year intervals), with a median observation period of ten years. RESULTS: Body height in affected children was shorter between years 1-9 of life with a nadir at age 1-3 years. Their height did not differ from general population at the age 10-12 years. There were not found differences according to 21OHD-CAH severity. CONCLUSIONS: NBS is an effective secondary prevention tool for the early detection of 21OHD-CAH which improves growth patterns. A significant growth deceleration was observed during infancy and early childhood periods but with following height normalization. Growth pattern was not associated with the genotype of 21OHD, if patients have been detected by NBS.

Center of Molecular Biology and Gene Therapy University Hospital of Brno Brno Czech Republic

Department of Children and Adolescents 3rd Faculty of Medicine Kralovske Vinohrady University Hospital Charles University Prague Czech Republic

Department of Pediatrics 2nd Faculty of Medicine Motol University Hospital Charles University Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc24007468

003      

CZ-PrNML

005      

20240423160005.0

007      

ta

008      

240412s2024 it f 000 0|eng||

009      

AR

024    7_

$a 10.23736/S2724-5276.20.05795-3 $2 doi

035    __

$a (PubMed)32508077

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a it

100    1_

$a David, Jan $u Department of Children and Adolescents, Third Faculty of Medicine, Kralovske Vinohrady University Hospital, Charles University, Prague, Czech Republic - jan.david@fnmotol.cz $u Department of Pediatrics, Second Faculty of Medicine, Motol University Hospital, Charles University, Prague, Czech Republic - jan.david@fnmotol.cz

245    10

$a Newborn screening-detected 21-hydroxylase deficiency: growth pattern is not associated with the genotype / $c J. David, Z. Hrubá, S. Kolouâková, F. Votava

520    9_

$a BACKGROUND: Normalizing growth in children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD-CAH) requires a long-term maintenance of a fragile balance between hydrocortisone (HC) replacement and androgen suppression. The growth pattern in children with 21OHD-CAH diagnosed by clinical symptoms has been evaluated in numerous retrospective studies. The aim of this study was to evaluate growth of patients with 21OHD-CAH detected by newborn screening (NBS), prior to clinical symptoms. METHODS: Nation-wide NBS for 21OHD-CAH was implemented in the Czech Republic in 2006. Since then, 1,317,987 neonates were screened (2006-2017) and 21OHD-CAH was confirmed in 108 patients. Growth was evaluated as height-standard deviation score (SDS) at regular time-points, related to bone age and compared to recent population standards. In 88 patients, available data allowed long-term evaluation of growth, HC and fludrocortisone doses (in half-year intervals), with a median observation period of ten years. RESULTS: Body height in affected children was shorter between years 1-9 of life with a nadir at age 1-3 years. Their height did not differ from general population at the age 10-12 years. There were not found differences according to 21OHD-CAH severity. CONCLUSIONS: NBS is an effective secondary prevention tool for the early detection of 21OHD-CAH which improves growth patterns. A significant growth deceleration was observed during infancy and early childhood periods but with following height normalization. Growth pattern was not associated with the genotype of 21OHD, if patients have been detected by NBS.

650    _2

$a dítě $7 D002648

650    _2

$a novorozenec $7 D007231

650    _2

$a lidé $7 D006801

650    _2

$a předškolní dítě $7 D002675

650    _2

$a kojenec $7 D007223

650    12

$a kongenitální adrenální hyperplazie $x diagnóza $x genetika $7 D000312

650    _2

$a retrospektivní studie $7 D012189

650    _2

$a novorozenecký screening $7 D015997

650    _2

$a hydrokortison $x terapeutické užití $7 D006854

650    _2

$a genotyp $7 D005838

655    _2

$a časopisecké články $7 D016428

700    1_

$a Hrubá, Zuzana $u Center of Molecular Biology and Gene Therapy, University Hospital of Brno, Brno, Czech Republic

700    1_

$a Kolouâková, Stanislava $u Department of Pediatrics, Second Faculty of Medicine, Motol University Hospital, Charles University, Prague, Czech Republic

700    1_

$a Votava, Felix $u Department of Children and Adolescents, Third Faculty of Medicine, Kralovske Vinohrady University Hospital, Charles University, Prague, Czech Republic

773    0_

$w MED00209466 $t Minerva pediatrics $x 2724-5780 $g Roč. 76, č. 1 (2024), s. 24-29

856    41

$u https://pubmed.ncbi.nlm.nih.gov/32508077 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20240412 $b ABA008

991    __

$a 20240423160001 $b ABA008

999    __

$a ok $b bmc $g 2081456 $s 1217235

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2024 $b 76 $c 1 $d 24-29 $e 20200605 $i 2724-5780 $m Minerva pediatrics $n Minerva Pediatr (Torino) $x MED00209466

LZP    __

$a Pubmed-20240412